Skip to content

    Asthma Health Center

    Font Size
    A
    A
    A

    FDA OKs New Once-Daily Asthma Treatment

    By
    Medscape Medical News

    Aug. 21, 2014 -- The FDA has approved Arnuity Ellipta (fluticasone furoate inhalation powder), an inhaled steroid taken once a day to prevent asthma symptoms in people 12 and older, drugmaker GlaxoSmithKline says.

    Arnuity Ellipta has been tested in more than 3,600 people with asthma, the company says in a statement. The most common side effects (reported in at least 5% of people) were upper respiratory tract infection, common cold, headache, and bronchitis.

    Arnuity Ellipta helps prevent an asthma attack but doesn’t treat it once it happens, so you still need your rescue inhaler.

    Arnuity Ellipta should not be used if you have a severe milk allergy.

    Side effects are similar to those of other inhaled steroids. For example, some people who take Arnuity Ellipta may develop a yeast infection in their mouth.

    Close monitoring for glaucoma and cataracts is also needed, the company says.

    GlaxoSmithKline says more information, including a patient information leaflet, will be available soon on its web site.

    With reporting by Megan Brooks, Medscape Medical News

    When Is Your Asthma Worse?

    When Is Your Asthma Worse?

    Take the WebMD Asthma assessment to get Personalized Action Plan

    Start Now

    Today on WebMD

    Lung and bronchial tube graphic
    5 common triggers.
    group jogging in park
    Should you avoid fitness activities?
     
    asthma inhaler
    Learn about your options.
    man feeling faint
    What’s the difference?
     
    Madison Wisconsin Capitol
    Slideshow
    woman wearing cpap mask
    Article
     
    red wine pouring into glass
    Slideshow
    Woman holding inhaler
    Quiz
     
    Man outdoors coughing
    Article
    Lung and bronchial tube graphic
    Article
     
    10 Worst Asthma Cities
    Slideshow
    runner
    Article